Key Contact: Phil Pugh
Author: Ffion Morgan
Acuity Law is pleased to have advised IX Group Limited on the sale of its subsidiaries, Rephine Limited, Rephine Sourcing Limited and Medix UK Limited (together, Rephine) to Kester Capital, a primary buyout specialist.
Rephine is a pioneering consultancy business that provides a wide range of clinical and regulatory services to pharmaceutical, medical device and biotechnology industries. Rephine’s audit library model has facilitated rapid business growth and with offices in India and Turkey as well as the UK, the customer reach is worldwide. Rephine’s new partnership with Kester will allow it to expand its service offering into other good working practice audit areas to meet increasing demands in the pharmaceutical supply chains.
Rino Coladangelo, retiring CEO, said “I am proud to have led Rephine to this point and am pleased to be handing over to Adam, Maureen and the Kester team. I am confident their experience and expertise, supported by the great existing team, will take Rephine to the next level.
Acuity Law supported us throughout the sale process with great skill and patience, and not just passively responding to requests but often actively proposing constructive strategies and tactics. It has been a pleasure to work with Acuity Law on this project.”
Corporate Partner, Phil Pugh commented “We thoroughly enjoyed working with Rino and the team. Rephine is a fantastic business with outstanding prospects. We wish the company every success in its future endeavours.”
Phil led the transaction with support from Natalie Jones, Chiara Howfield, Ffion Morgan and cross departmental support from Adam McGlynn and Emma Hutchings.
Find out more about our award-winning Corporate Team and how to contact them here.
